LONDON (Alliance News) - Proteome Sciences PLC Chief Executive Officer Jeremy Haigh said Wednesday at the company's annual general meeting trading in the year-to-date has been in line despite a slower first quarter.
"As stated in our recent results, we expect 2018 to be a year of progress as we develop our biomarker services business and the market for TMT strengthens," Haigh added.
The company remains cash constraint but had talks with its larger shareholders who said they will provide non-dilutive funding if needed.
Proteome shares were trading 8.0% higher Wednesday at 3.67 pence each.
Proteome (PRM)